Healthcare Realty Trust Incorporated
HR
$21.47
+1.04%
Healthcare Realty Trust Incorporated is a real estate investment trust (REIT) that focuses on owning, leasing, and managing outpatient medical facilities and other healthcare properties across the United States. As a specialized healthcare REIT, it differentiates itself by concentrating on outpatient facilities that are integral to hospital operations, providing a stable income stream through long-term leases. The current investor narrative centers on the company's ongoing portfolio optimization and balance sheet deleveraging efforts, as it navigates a period of revenue contraction and net losses while seeking to improve operational efficiency and capitalize on the growing demand for outpatient care.…
HR
Healthcare Realty Trust Incorporated
$21.47
HR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthcare Realty Trust Incorporated's 12-month outlook, with a consensus price target around $21.33 and implied upside of -0.6% versus the current price.
Average Target
$21.33
0 analysts
Implied Upside
-0.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $24
Analyst target range
The stock is covered by 12 analysts, with a consensus recommendation of 'hold' and a mean recommendation score of 2.54 (on a scale where 1 is strong buy and 5 is strong sell). The average target price is $21.33, essentially flat relative to the current price of $21.32, implying no upside. The distribution shows a mix of neutral and bullish ratings, with firms like Cantor Fitzgerald and Scotiabank maintaining 'Overweight' and 'Sector Outperform' ratings, while JP Morgan, UBS, and Citigroup hold 'Neutral' or 'Equal Weight' stances. The target price range spans from $18.00 (low) to $24.00 (high), representing a 33% spread between the low and high estimates. The low target of $18.00 implies a 15.6% downside from current levels, likely pricing in continued revenue contraction or margin pressure, while the high target of $24.00 suggests 12.6% upside, assuming successful portfolio optimization and margin recovery. The wide spread indicates significant uncertainty about the company's near-term performance, and the lack of recent rating changes (most actions were reaffirmations) suggests analysts are in a wait-and-see mode.
Drowning in data?
Find the real signal!
Bulls vs Bears: HR Investment Factors
Healthcare Realty Trust presents a mixed picture. On the bullish side, strong price momentum, improving gross margins, positive TTM free cash flow, and a low P/S ratio relative to history support the case for a turnaround. However, persistent revenue declines, net losses, high leverage, and a flat analyst target price highlight significant risks. The most important tension is whether the company can stabilize revenues and achieve sustained profitability. If gross margin improvements continue and revenue contraction reverses, the stock could re-rate higher. Conversely, if revenue declines persist and profitability remains elusive, the current valuation premium may not be justified. Currently, the bear case has slightly stronger evidence due to the lack of revenue growth and profitability, but the improving margins and cash flow provide a path to recovery.
Bullish
- Strong Price Momentum: The stock has gained 31.6% over the past year, significantly outperforming the S&P 500's 18.4% return. The current price of $21.32 is near the 52-week high of $21.47, indicating strong bullish sentiment and momentum.
- Improving Gross Margin: Gross margin turned positive at 64.1% in Q1 2026, a dramatic reversal from negative gross margins in prior quarters (e.g., -36.3% in Q2 2025). This suggests successful cost structure improvements and operational efficiency gains.
- Positive Free Cash Flow TTM: Despite negative free cash flow of -$8.28M in the most recent quarter, trailing twelve-month free cash flow is positive at $140.0M. This indicates the company can generate cash over a longer horizon, supporting dividend payments and deleveraging.
- Low Valuation vs. History: The trailing P/S ratio of 5.02x is near the low end of its five-year historical range of 16x-35x, suggesting the stock may be undervalued relative to its own history. If the company stabilizes revenues and returns to profitability, multiple expansion could drive upside.
Bearish
- Declining Revenue Trend: Revenue declined 6.7% year-over-year in Q1 2026 to $278.99M, continuing a trend from $298.98M in Q1 2025. This contraction raises concerns about the company's ability to grow its portfolio and generate organic growth.
- Persistent Net Losses: The company reported a net loss of $56,000 in Q1 2026, though improved from a loss of $157.85M in Q2 2025. However, trailing twelve-month net income remains negative, and ROE is -5.3%, indicating ongoing profitability challenges.
- High Leverage and Interest Burden: Debt-to-equity is 0.90, and the interest coverage ratio of 0.77x indicates earnings are insufficient to cover interest expenses. This financial risk could pressure the stock if interest rates remain elevated or if cash flow deteriorates.
- Limited Analyst Upside: The consensus analyst target price is $21.33, essentially flat relative to the current price of $21.32, implying no upside. The low target of $18.00 suggests a potential 15.6% downside, reflecting significant uncertainty.
HR Technical Analysis
Healthcare Realty Trust is in a sustained uptrend, with the stock price up 31.6% over the past year, significantly outperforming the S&P 500's 18.4% gain. The current price of $21.32 sits at 99.3% of its 52-week range ($15.29–$21.47), indicating the stock is near its highs and reflecting strong momentum. This positioning suggests bullish sentiment but also raises caution about potential overextension, as the stock may be pricing in optimistic expectations. Short-term momentum is accelerating, with the stock gaining 6.5% in the past month and 14.9% over the past three months, both outpacing the S&P 500's 0.3% and 4.7% returns, respectively. The 1-month relative strength of 6.2% confirms the stock's recent outperformance, and the consistent upward trajectory from the 52-week low of $15.29 to current levels indicates a strong recovery trend without significant divergence. Key technical support lies near the 52-week low of $15.29, while resistance is at the 52-week high of $21.47. A breakout above $21.47 would signal a continuation of the uptrend, potentially opening room for further gains, while a breakdown below $15.29 would indicate a reversal. The stock's beta of 0.82 suggests it is less volatile than the overall market, making it a relatively defensive holding within the REIT sector.
Beta
0.82
0.82x market volatility
Max Drawdown
-13.4%
Largest decline past year
52-Week Range
$15-$21
Price range past year
Annual Return
+32.4%
Cumulative gain past year
| Period | HR Return | S&P 500 |
|---|---|---|
| 1m | +8.5% | +0.2% |
| 3m | +17.3% | +5.2% |
| 6m | +26.6% | +8.6% |
| 1y | +32.4% | +19.0% |
| ytd | +26.7% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HR Fundamental Analysis
Revenue has been declining, with the most recent quarterly revenue of $278.99 million down 6.7% year-over-year, and the trend shows a deceleration from $298.98 million in Q1 2025 and $297.77 million in Q3 2025. The company's revenue segments include management fee income of $5.63 million and parking income of $2.07 million, but these are small relative to total revenue, indicating that property leasing is the primary driver. The revenue contraction raises concerns about the company's ability to grow its portfolio and generate organic growth, which is critical for the investment case. The company is currently unprofitable, with a net loss of $56,000 in the most recent quarter, though this is a significant improvement from the net loss of $157.85 million in Q2 2025. Gross margin turned positive at 64.1% in Q1 2026, a sharp reversal from negative gross margins in prior quarters (e.g., -36.3% in Q2 2025), suggesting cost structure improvements. However, the net margin remains near zero at -0.02%, and the trailing twelve-month net income is negative, indicating that profitability remains elusive. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.90 and a current ratio of 1.75, indicating adequate short-term liquidity. Free cash flow was negative $8.28 million in the most recent quarter, but trailing twelve-month free cash flow is positive at $140.0 million, suggesting the company can generate cash over a longer horizon. ROE is negative at -5.3%, reflecting the net loss position, and the company's reliance on debt financing (debt-to-equity of 0.90) adds financial risk, though the interest coverage ratio of 0.77x indicates earnings are insufficient to cover interest expenses.
Quarterly Revenue
$278990000.0B
2026-03
Revenue YoY Growth
-6.7%
YoY Comparison
Gross Margin
64.1%
Latest Quarter
Free Cash Flow
$140005000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HR Overvalued?
Given that net income is negative (trailing EPS of -$0.04), the price-to-sales (P/S) ratio is the primary valuation metric. The trailing P/S ratio is 5.02x, while the EV/Sales multiple is 10.12x, reflecting the company's debt load. The forward P/E of 1,066x is not meaningful due to near-zero earnings, but the gap between trailing and forward metrics implies the market expects a return to profitability. Compared to the industry average (not provided), the P/S of 5.02x appears elevated for a REIT with declining revenues and negative earnings, suggesting a premium that may be justified by the company's focus on outpatient facilities and potential for recovery. Historically, the stock's P/S ratio has ranged from approximately 16x to 35x over the past five years, with the current 5.02x near the low end of that range. This low multiple relative to history could indicate a value opportunity if the company can stabilize revenues and return to profitability, but it may also reflect the market's skepticism about near-term growth prospects.
PE
-23.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~184x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The company's primary financial risk is its inability to generate consistent profits, with a trailing net loss and negative ROE of -5.3%. Revenue has declined 6.7% YoY, and the interest coverage ratio of 0.77x indicates that operating income is insufficient to cover interest expenses, raising concerns about debt servicing. The debt-to-equity ratio of 0.90 is moderate but elevated for a REIT, and negative free cash flow in the most recent quarter (-$8.28M) could pressure liquidity if the trend continues. Market & Competitive Risks: The stock trades at a P/S of 5.02x, which is low relative to its own history but may still be elevated for a company with declining revenues and negative earnings. The beta of 0.82 provides some defense, but the stock is highly sensitive to interest rate changes, as REITs typically underperform in rising rate environments. The consensus 'hold' rating and flat analyst target price suggest limited near-term upside, and the wide target range ($18-$24) indicates high uncertainty. Worst-Case Scenario: If revenue continues to decline and the company fails to achieve sustained profitability, the stock could fall to the analyst low target of $18.00, representing a 15.6% downside from the current price of $21.32. In a severe downturn, the stock could revisit its 52-week low of $15.29, implying a 28.3% loss. This scenario could be triggered by a broader economic recession, rising interest rates compressing REIT multiples, or a failure to execute portfolio optimization.
